Navigation Links
Adrenaline receptor 'frozen in action' by VIB researchers
Date:1/12/2011

Brussels - Adrenaline, the hormone that prepares our body to fight or flight, acts on a hyperdynamic receptor. This molecule switches so fast between several positions, that it was impossible to image it. Until now. Scientists, including Jan Steyaert of VIB and the Vrije Universiteit Brussel in Belgium, and colleagues from Stanford University in the US, have "frozen the molecule in action" using Xaperones, tiny, stable antibodies developed by the Brussels scientists. The Xaperones bind like a key to a lock, holding the adrenaline receptor in one position -- the on position. After binding the adrenaline receptor to the Xaperone, the researchers could use X-ray crystallography techniques to determine its structure. The results are published in Nature.

Prospects for medicine

The breakthrough is not only a scientific first, the newly developed technique also offers promising prospects for medicine. The adrenaline switch is the target of widely used drugs such as asthma inhibitors and beta blockers. The latter are used worldwide as a medicine for heart disease.

But the applications are not limited to asthma or heart disease. Over 30% of all drugs on sale in pharmacies today switch similar receptors on or off. Through the newly developed technique, these receptors can now be accurately described, which is a necessary first step to determine their action and develop new or better drugs.

Receptors as switches in the body

Adrenaline is a hormone that is released under stress. It is a messenger molecule which causes the heart to beat faster, causes us to sweat suddenly and releases sugar as an immediately usable source of energy. These reactions are the result of the fact that adrenaline binds with a specific switch (known as beta2-adrenergic receptor). This switch is embedded in the membrane surrounding our cells. When adrenaline binds to the receptor, the individual cell knows that the rest of the body is preparing for stress reactions such as fight or flight.

It is impossible to determine the structure of this kind of switches by using conventional methods. They move, oscillate and constantly change position, even when the signalling molecule such as adrenaline is absent. Together with researchers from Stanford University, Jan Steyaert and his colleagues have managed as it were to freeze the adrenaline switch in the "on" position. For this purpose, they used a Xaperone which attaches like a key in a lock to the switch and causes it to stop switching from one position to another. It is in this "frozen" on-position that the structure was determined using X-ray crystallography techniques.

Our body is equipped with hundreds of similar continually moving switches which determine how we react to our environment. The scientific term for these switches is GPCR (G-Protein-coupled receptors). The newly developed technique based on Xaperones can also be widely used in studying other GPCRs and proteins with therapeutic relevance.

Xaperones is a new application of the Nanobody technology developed at VIB-Vrije Universiteit Brussel. The development of therapeutic Nanobodies forms the basis of the biopharmaceutics company Ablynx, a start-up of VIB and Vrije Universiteit Brussel.

Frozen in action

The solution to fix proteins with Xaperones is comparable to the solution which the English scholar Eadweard Muybridge conceived of around 1900 to be able to study fast-moving objects. He was the first to prove, on the basis of a series of still photographs, that a galloping horse sometimes has all its legs off the ground. http://en.wikipedia.org/wiki/Eadweard_Muybridge


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Carnegie Mellon researchers discover mechanism for signaling receptor recycling
2. Discovery of taste receptors in the lungs could help people with asthma breathe easier
3. Amid the murk of gut flora, vitamin D receptor emerges as a key player
4. Connecting the dots: How light receptors get their message across
5. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
6. Receptor variant influences dopamine response to alcohol
7. Gene-based stem cell therapy specifically removes cell receptor that attracts HIV
8. Stress peptide and receptor may have role in diabetes
9. Developmental delay could stem from nicotinic receptor deletion
10. Common herbicides and fibrates block nutrient-sensing receptor found in gut and pancreas
11. Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Alex,s Lemonade Stand ... that that it will open a state-of-the-art bioinformatics lab, ... cancer research. This announcement comes as Liz Scott ... the National Cancer Moonshot Summit in Washington, ... Biden as a participant and advocate of pediatric cancer ...
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
Breaking Biology Technology: